Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DBVT NASDAQ:ELVN NASDAQ:GMTX NASDAQ:IDYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$13.90+2.0%$16.45$8.51▼$26.18$807.06M-0.95250,480 shs380,748 shsELVNEnliven Therapeutics$52.74-0.4%$45.75$14.78▼$55.79$3.22B0.24864,791 shs1.41 million shsGMTXGemini Therapeutics$74.12-2.3%$71.77$1.16▼$14.10$3.21B-0.12189,291 shs403,436 shsIDYAIDEAYA Biosciences$36.77+3.9%$33.15$22.09▼$40.58$3.11B-0.09968,459 shs1.17 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies+1.98%-4.60%-13.83%-33.17%+45.26%ELVNEnliven Therapeutics-0.40%+2.07%+5.31%+22.71%+148.77%GMTXGemini Therapeutics0.00%-2.67%-0.88%+7.65%+22.29%IDYAIDEAYA Biosciences+3.87%+3.72%+0.08%+26.46%+50.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$13.90+2.0%$16.45$8.51▼$26.18$807.06M-0.95250,480 shs380,748 shsELVNEnliven Therapeutics$52.74-0.4%$45.75$14.78▼$55.79$3.22B0.24864,791 shs1.41 million shsGMTXGemini Therapeutics$74.12-2.3%$71.77$1.16▼$14.10$3.21B-0.12189,291 shs403,436 shsIDYAIDEAYA Biosciences$36.77+3.9%$33.15$22.09▼$40.58$3.11B-0.09968,459 shs1.17 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies+1.98%-4.60%-13.83%-33.17%+45.26%ELVNEnliven Therapeutics-0.40%+2.07%+5.31%+22.71%+148.77%GMTXGemini Therapeutics0.00%-2.67%-0.88%+7.65%+22.29%IDYAIDEAYA Biosciences+3.87%+3.72%+0.08%+26.46%+50.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVTDBV Technologies 2.71Moderate Buy$48.50248.92% UpsideELVNEnliven Therapeutics 2.86Moderate Buy$70.5033.67% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AIDYAIDEAYA Biosciences 2.81Moderate Buy$50.2536.66% UpsideCurrent Analyst Ratings BreakdownLatest DBVT, ELVN, GMTX, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026ELVNEnliven Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$59.00 ➝ $67.007/17/2026DBVTDBV Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/17/2026ELVNEnliven Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026IDYAIDEAYA Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026ELVNEnliven Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $64.007/7/2026IDYAIDEAYA Biosciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$53.00 ➝ $48.007/7/2026IDYAIDEAYA Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $63.007/1/2026ELVNEnliven Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $80.006/30/2026DBVTDBV Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026DBVTDBV Technologies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$47.00 ➝ $55.006/29/2026DBVTDBV Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVTDBV Technologies$5.64M145.93N/AN/A$4.20 per share3.31ELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/AGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AIDYAIDEAYA Biosciences$225.27M14.34N/AN/A$11.67 per share3.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVTDBV Technologies-$146.95M-$3.51N/AN/AN/A-3,506.53%-119.33%-84.43%N/AELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AIDYAIDEAYA Biosciences-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%8/10/2026 (Estimated)Latest DBVT, ELVN, GMTX, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026ELVNEnliven Therapeutics-$0.38N/AN/AN/AN/AN/A8/10/2026Q2 2026IDYAIDEAYA Biosciences-$1.0613N/AN/AN/A$8.02 millionN/A7/16/2026Q2 2026DBVTDBV Technologies-$0.12-$0.60-$0.48-$0.60$0.90 million$0.70 million5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/5/2026Q1 2026IDYAIDEAYA Biosciences-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 million4/30/2026Q4 2025DBVTDBV Technologies-$0.14-$0.56-$0.42-$0.55$1.11 million$0.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDBVTDBV TechnologiesN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVTDBV TechnologiesN/A3.723.72ELVNEnliven TherapeuticsN/A40.3240.32GMTXGemini TherapeuticsN/A71.4971.49IDYAIDEAYA BiosciencesN/A10.7410.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVTDBV Technologies71.74%ELVNEnliven Therapeutics95.08%GMTXGemini Therapeutics75.42%IDYAIDEAYA Biosciences98.29%Insider OwnershipCompanyInsider OwnershipDBVTDBV Technologies1.06%ELVNEnliven Therapeutics3.00%GMTXGemini Therapeutics12.90%IDYAIDEAYA Biosciences4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVTDBV Technologies8059.21 million58.58 millionOptionableELVNEnliven Therapeutics5060.91 million59.08 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableIDYAIDEAYA Biosciences8087.86 million83.73 millionOptionableDBVT, ELVN, GMTX, and IDYA HeadlinesRecent News About These CompaniesIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted ...July 27 at 1:21 PM | finance.yahoo.comIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung CancersJuly 27 at 6:00 AM | prnewswire.comIDEAYA Biosciences Inc IDYAJuly 26 at 2:29 PM | morningstar.comMJennison Associates LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYAJuly 22, 2026 | marketbeat.comIDEAYA Biosciences, Inc. $IDYA Stake Trimmed by WCM Investment Management LLCJuly 21, 2026 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 21, 2026 | americanbankingnews.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by AnalystsJuly 21, 2026 | marketbeat.comIDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical ProgramsJuly 17, 2026 | prnewswire.comIDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA FilingJuly 16, 2026 | theglobeandmail.comIDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology SummitJuly 15, 2026 | theglobeandmail.comIDEAYA Biosciences Analyst Ratings and Price Targets | NASDAQ:IDYA | BenzingaJuly 14, 2026 | benzinga.comCandriam S.C.A. Boosts Stake in IDEAYA Biosciences, Inc. $IDYAJuly 12, 2026 | marketbeat.comInsider Selling: IDEAYA Biosciences (NASDAQ:IDYA) CAO Sells $382,095.50 in StockJuly 10, 2026 | insidertrades.comInsider Selling: IDEAYA Biosciences (NASDAQ:IDYA) CAO Sells 9,550 Shares of StockJuly 9, 2026 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 26, 2026 | prnewswire.comIDEAYA Biosciences Shareholders Back Leadership, Governance ChangesJune 23, 2026 | tipranks.comIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of DirectorsJune 17, 2026 | prnewswire.comIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and ...June 15, 2026 | finance.yahoo.comIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung CancersJune 15, 2026 | prnewswire.comIDEAYA Biosciences (IDYA) Receives a Buy from GuggenheimJune 14, 2026 | theglobeandmail.comIdeaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026June 11, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDBVT, ELVN, GMTX, and IDYA Company DescriptionsDBV Technologies NASDAQ:DBVT$13.90 +0.27 (+1.98%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$13.92 +0.03 (+0.18%) As of 07/27/2026 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Enliven Therapeutics NASDAQ:ELVN$52.74 -0.21 (-0.40%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$52.82 +0.09 (+0.16%) As of 07/27/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Gemini Therapeutics NASDAQ:GMTX$74.12 -1.74 (-2.29%) As of 07/24/2026Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.IDEAYA Biosciences NASDAQ:IDYA$36.77 +1.37 (+3.87%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$36.82 +0.04 (+0.12%) As of 07/27/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
